Skip to main content

Name
Daniel Rivera

Tue, 09/24/2019 - 19:09

Doing research in a field quite different from cardiovascular metabolomics, I was unsure of what I may take away from Dr. Gerszten's Grand Rounds presentation. After his engaging presentation and the following small group discussion, I can say I am leaning towards the stance that metabolomics may be be the next big thing in biomedical science, leaving me more convinced about its potential applications in a variety of fields. An interesting discussion took place between Dr. Gerszten and a fellow student and member of the research unit I am based out of, discussing the potential application of metabolomics in predicting risk of IBS or IBD. Dr. Gerszten was cautious about asserting that the work already done via metabolomics and such a disease/disease models would hold up, but shed light on various challenges the field must overcome (controlling for various experimental variables) in order improve reproducibility of such metabolomic experiments. Despite his caution, his comments were encouraging and suggested that meaningful application of metabolomics in such a field can be achieved.

As the scientific community, researchers and funding agencies alike, begin to reinvigorate their interest in the applications of metabolomics in the study of various diseases (as Dr. Gerszten had suggested is already taking place), I believe metabolomics will come to be an important clinical diagnostic and prognostic tool. We're not quite yet there - there are obstacles that must be overcome in a number of fields and perhaps with the technology itself - but Dr. Gerszten's presentation and the work he presented have made be a believer that we may just be on the precipice of a breakthrough that will radiate clinical and basic science specialties/fields. Dr. Gerszten compared the metabolomics/proteomics movement to the Human Genome Project (HGP). Like the HGP, I hope collaboration and public and scientific interest drive further exploration of metabolomics such that it may, if it holds up, revolutionize clinical practice.

It was a pleasure to attend this Grand Rounds - thank you, Dr. Gerszten!

Name
Daniel Rivera

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.